BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29396560)

  • 21. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
    Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
    J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
    Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
    J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
    Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
    Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
    Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
    Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Circulating Tumor Cells in Predicting Therapeutic Response in Small Cell Lung Cancer Patients.
    Wang X; Ma K; Wang Y; He H; Hu JF; Li W
    Arch Med Res; 2016 Aug; 47(6):454-459. PubMed ID: 27986125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
    Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
    Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical significance of circulating tumor cells in patients with small-cell lung cancer.
    Wang YL; Liu CH; Li J; Ma XP; Gong P
    Tumori; 2017 May; 103(3):242-248. PubMed ID: 28218384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.
    Hofman V; Ilie MI; Long E; Selva E; Bonnetaud C; Molina T; Vénissac N; Mouroux J; Vielh P; Hofman P
    Int J Cancer; 2011 Oct; 129(7):1651-60. PubMed ID: 21128227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.
    Koinis F; Zafeiriou Z; Messaritakis I; Katsaounis P; Koumarianou A; Kontopodis E; Chantzara E; Aidarinis C; Lazarou A; Christodoulopoulos G; Emmanouilides C; Hatzidaki D; Kallergi G; Georgoulias V; Kotsakis A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
    Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
    J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
    Wu C; Hao H; Li L; Zhou X; Guo Z; Zhang L; Zhang X; Zhong W; Guo H; Bremner RM; Lin P
    J Thorac Oncol; 2009 Jan; 4(1):30-6. PubMed ID: 19096303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
    Georgoulias V; Apostolaki S; Bozionelou V; Politaki E; Perraki M; Georgoulia N; Kalbakis K; Kotsakis A; Xyrafas A; Agelaki S; Mavroudis D
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1217-25. PubMed ID: 25344760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system.
    Ikeda M; Koh Y; Teraoka S; Sato K; Kanai K; Hayata A; Tokudome N; Akamatsu H; Ozawa Y; Akamatsu K; Endo K; Higuchi M; Nakanishi M; Ueda H; Yamamoto N
    Cancer Med; 2020 Mar; 9(6):2122-2133. PubMed ID: 31999390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Tamminga M; Andree KC; van den Bos H; Hiltermann TJN; Mentink A; Spierings DCJ; Lansdorp P; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    Br J Cancer; 2022 Feb; 126(3):409-418. PubMed ID: 34848855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detecting circulating tumor cells in patients with advanced non-small cell lung cancer.
    Xu YH; Zhou J; Pan XF
    Genet Mol Res; 2015 Sep; 14(3):10352-8. PubMed ID: 26345975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.
    Kallergi G; Aggouraki D; Zacharopoulou N; Stournaras C; Georgoulias V; Martin SS
    Breast Cancer Res; 2018 Jul; 20(1):67. PubMed ID: 29976237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.